Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
An open letter to President Biden
Mr. Joseph Biden
President of the United States
The White House
1600 Pennsylvania Avenue, N.W.
Washington, DC 20500
Dear President Biden,
Your recent six executive orders addressing gun reforms are a step in the right direction, but I think we can both agree that they do not even begin to address the gun violence crisis gripping the United States. Even if you were able to achieve two-thirds of the Senate to embrace new firearms legislation, it’s already too late - the horse has left the proverbial barn. There are more guns than people in the United States, and the complexity of limiting use to only legal and peaceful purposes is beyond the reach of any legislation or law enforcement agency.
So, respectfully, your six executive orders serve only as a symbolic reaction to the gun violence epidemic.
There is a way to move beyond symbolism, in the same manner as your green energy programs. I propose a different approach - one that can be readily implemented today, and is both progressive and pre-emptive.
Technology exists today to pro-actively detect and alert on a threat from weapons within milli-seconds, alerting authorities, or systems that can lock-down schools, retail locations, places of worship, and other targets of violence.
I am not here to debate guns rights. That is not the purpose here, and a discussion for a different forum.
I am here to propose that, no matter what side of the gun rights discussion, we have the technical means and an obligation to use that technology to stop or drastically minimize these tragic events. The only logical answer is to redirect our attention to helping organizations protect their places of operation, and pre-emptively alert on threats.
Modern gun and threat detection technology makes this possible - the only thing that’s stopping it from curbing the gun violence epidemic is adoption.
To solve the adoption problem, I would direct you to a recent example of how government has successfully promoted adoption of a technology beneficial to society: solar energy.
When you started your first job in the executive branch as vice president, solar energy was a bit of a curiosity, installed only by environmentalists with disposable income. But then, government got involved in a productive fashion and provided incentives for solar adoption. This turbocharged market demand and, in 2020, solar represented 43% of all new electricity-generating capacity added in the United States.
Imagine, if you will, taking a similar approach with gun safety. What if the government provided businesses, local governments, educational institutions, etc. with tax incentives to install gun detection technology to make the places where people gather safe from gun violence? The managers inside that Boulder grocery store, or the Fedex facility, could have detected the assailant’s weapons when he was getting out of his car in the parking lot. The store would have been automatically locked down, and authorities alerted before the first step, limiting or eliminating the damage done.
Like so many industries where digital innovation has re-invented markets and delivered benefits to the community at large, digital innovation in weapons detection and threat response can provide a means for communities to “harden” themselves to gun violence. Digital technology can be used to provide a multi-layered approach to early detection, early alerting, and pre-emptive and proactive protection. These solutions scale, are always-on, are cost-effective, can be deployed in all buildings and venues, and provide advanced information not available to solutions based on human observation.
Providing businesses and communities with adoption incentives for these technologies is the most readily achievable way for the country to finally put a measurable dent in the gun violence epidemic - and since it does not bring the Second Amendment into play, it would likely have bipartisan support.
After a detailed analysis of the tragic and unfortunate incidents in Boulder, Indianapolis, and other locations over the past few months, I can say, with a heavy heart, that all of them could have been made less severe – or prevented all together – if the locations where they occurred had early warnings from modern gun and threat detection technology.
You, Sir, could be the President whose legacy includes elimination of tragic shootings.
I would be very interested in scheduling a meeting with you to discuss this further.
Sincerely,
Peter Evans
CEO, Patriot One Technologies
Dumping or everyone’s stops being taken out???
You do mean 150,000 not 1,500,000 correct?
Either way you need to break up the trades in smaller lots.
Algernon Announces First U.S. Clinical Trial Site in Florida for Phase 2b/3 Human Study of Ifenprodil for COVID-19
C.AGN | 12 minutes ago
VANCOUVER, British Columbia, July 16, 2020 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to announce that it has completed its clinical trial agreement with Westchester Research Center at Westchester General Hospital in Miami, Florida, for its multinational Phase 2b/3 human study of NP-120 (Ifenprodil) for COVID-19. The principal investigator is Dr. Aimee Gonzalez, MD. Ifenprodil is an NMDA receptor antagonist specifically targeting the NMDA-type subunit 2B.
The Company is planning to conduct a site initiation visit at Westchester General Hospital during the week of July 20, 2020 and enrolment of patients in the study can begin shortly thereafter.
The Company is in final contractual negotiations with 4 additional U.S. clinical sites. The Company has already received ethics approval from a central institutional review board for all of the U.S. study sites. The Company is also in the final stages of completing contractual negotiations and receiving ethics approval in Australia, Romania and the Philippines.
“Of the 5 U.S. research institutions we have been working with, two are located in Florida where they have recently had a significant number of confirmed COVID-19 cases,” said Christopher J. Moreau CEO of Algernon Pharmaceuticals. “We look forward to working with Dr. Gonzalez and appreciate her work in helping to get the trial started at Westchester General as soon as possible.”
Background
The Company announced on March 06, 2020 that it was going to explore Ifenprodil as a possible treatment for COVID-19 when it discovered an independent research study that showed the drug was active in an animal model for H5N1, the world’s most lethal avian flu, with an approximately 60% mortality rate in humans. In the study, Ifenprodil reduced mortality by 40% and reduced acute lung injury and inflammation in the lung tissue.
Coupled with the Company’s own animal data showing Ifenprodil’s reduction of lung fibrosis in two separate studies, the Company is investigating Ifenprodil to determine if it can reduce the severity and duration of a COVID infection.
Phase 2b/3 Study Protocol Summary
The Company’s multinational Phase 2b/3 human trial for COVID-19 is entitled, "A Randomized Open Label Phase 2b/3 Study of the Safety and Efficacy of NP-120 (Ifenprodil) for the Treatment of Hospitalized Patients with Confirmed COVID-19 Disease."
The trial will begin as a Phase 2b study of an aggregate of 150 patients. With positive preliminary data, the clinical trial will move directly into a Phase 3 trial. The data will determine the number of expected patients needed to reach statistical significance in the Phase 3 trial.
Patients will be randomized in a one-to-one manner and will either be treated using an existing standard of care, or standard of care plus Ifenprodil 60 mg (taken as one 20 mg tablet three-times daily) for one arm or standard of care plus Ifenprodil 120 mg (taken as two 20 mg tablets three-times daily) for two weeks.
Over the testing period, doctors will observe whether there is an improvement in a number of secondary endpoints, including mortality, blood oxygen levels, time spent in intensive care and time to mechanical ventilation.
Trial Start Date
Enrollment of the 1st patient for the Phase 2b/3 study is expected before the end of July 2020. It is difficult to assess at this time what the enrollment rate for the study will be across all countries and all sites selected. After the study begins, the Company will make an assessment of the enrollment rate and will provide an update to the market on a projected completion date as well as when the data will be expected.
About NP-120 (Ifenprodil)
NP-120 (Ifenprodil) is an N-methyl-D-aspartate (NMDA) receptor antagonist specifically targeting the NMDA-type subunit 2B (Glu2NB). Ifenprodil prevents glutamate signalling. The NMDA receptor is found on many tissues including lung cells, T-cells, and neutrophils.
The Company believes NP-120 can reduce the infiltration of neutrophils and T-cells into the lungs where they can release glutamate and cytokines respectively. The latter can result in the highly problematic cytokine storm that contributes to the loss of lung function and ultimately death as has been reported in COVID-19 infected patients.
About Algernon Pharmaceuticals Inc.
Algernon is a drug re-purposing company that investigates safe, already approved drugs for new disease applications, moving them efficiently and safely into new human trials, developing new formulations and seeking new regulatory approvals in global markets. Algernon specifically investigates compounds that have never been approved in the U.S. or Europe to avoid off label prescription writing.
Algernon has filed new intellectual property rights globally for NP-120 (Ifenprodil) for the treatment of respiratory diseases and is working to develop a proprietary injectable and slow release formulation.
CONTACT INFORMATION
Christopher J. Moreau
CEO
Algernon Pharmaceuticals Inc.
604.398.4175 ext 701
info@algernonpharmaceuticals.com
investors@algernonpharmaceuticals.com
www.algernonpharmaceuticals.com.
Warrants in November and we’ll have 84,000,000
Warrants in November and we’ll have 84,000,000
US .31 +25%!!
IIROC just resumed trading but might take a few minutes
Algernon Receives U.S. FDA Clearance for Multinational Phase 2b/3 Human Study to Evaluate Ifenprodil as a Potential Therapeutic for COVID-19
IIROC Trading Halt - AGN
C.AGN | 22 minutes ago
VANCOUVER, BC, June 4, 2020 /CNW/ - The following issues have been halted by IIROC:
Company: Algernon Pharmaceuticals Inc.
CSE Symbol: AGN (all issues)
Reason: At the request of the Company Pending News
Halt Time (ET): 7:52 AM
IIROC can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. IIROC is the national self-regulatory organization which oversees all investment dealers and trading activity on debt and equity marketplaces in Canada.
SOURCE Investment Industry Regulatory Organization of Canada (IIROC) - Halts/Resumptions
HALTED before opening today - pending news
Here’s an example of a much smaller Pharma company with positive FDA feedback on their drug.
PhaseBio Pharmaceuticals (NASDAQ:PHAS) +81% after-hours as the Food & Drug Administration authorized the company to proceed with VANGARD, "a potentially pivotal clinical trial to evaluate PB1046 as a treatment for hospitalized COVID-19 patients who are at high risk for rapid clinical deterioration and acute respiratory distress syndrome."
PB1046 is an injected vasoactive intestinal peptide receptor agonist that targets VPAC receptors in the cardiovascular, pulmonary and immune systems; VIP has been observed to have potent bronchodilatory and immunomodulatory effects in the respiratory system.
Based on FDA feedback, the company believes "positive, clearly interpretable and clinically meaningful trial results may enable PhaseBio to submit a Biologics License Application."
LET’S GO!!!! Let’s blow this COVID out of these lungs!!!
Let’s go all the way from Texas!!!
Let’s go all the way from Texas!!!
Algernon Submits Application to Health Canada for Ifenprodil COVID-19 Phase 2b/3 Multinational Clinical Trial
C.AGN | 9 minutes ago
VANCOUVER, British Columbia, April 22, 2020 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to announce that it has submitted a Clinical Trial Application (CTA) to Health Canada for an NP-120 (Ifenprodil) COVID-19 Phase 2b/3 multinational clinical trial. The same study protocol is being prepared for submission to the U.S. FDA and Australian regulatory authorities.
The study will be an adaptive pilot to pivotal trial design based on guidance documents from the World Health Organization (WHO) to determine if Ifenprodil can improve clinical symptoms and reduce the number of COVID-19 infected patients from progressing to mechanical ventilation with intubation and death.
The trial will begin as a Phase 2b study and after an interim analysis is performed on the first 100 patients, the data will determine the number of expected patients needed to reach statistical significance in a Phase 3 trial. With positive preliminary data, the clinical trial would move directly from a Phase 2b into a Phase 3 without the time delay involved in having to submit a new Clinical Trial Application.
“We are very excited about having the potential opportunity to transition this Ifenprodil COVID-19 trial into a Phase 3 study based on positive preliminary data,” said Christopher J. Moreau CEO of Algernon. “Pending approval, we would be included with only a small handful of companies globally working with a potential drug treatment at a Phase 3 level on this disease.”
The Company cautions that it is in the early stages of clinical research and development and is not making any express or implied claims that NP-120 (Ifenprodil) is an effective treatment for acute lung injury (ALI), the COVID-19 virus, or any other medical condition at this time.
Phase 2b/3 Study Protocol Overview
The trial will begin as a Phase 2b study enrolling 100 patients with moderate/severe disease, which corresponds with a score of 4 or 5 on the WHO ordinal clinical scale. Patients will be randomized in a 1:1 fashion to receive either standard of care (SOC) or SOC and Ifenprodil (20 mg three times per day) for a two-week treatment period. An improvement in the ordinal clinical scale is the initial primary endpoint and a number of secondary endpoints including mortality, blood oxygen levels, time in the ICU and time to mechanical ventilation will be studied.
About NP-120 (Ifenprodil)
NP-120 (Ifenprodil) is an N-methyl-D-aspartate (NMDA) receptor antagonist specifically targeting the NMDA-type subunit 2B (Glu2NB). Ifenprodil prevents glutamate signalling. The NMDA receptor is found on many tissues including lung cells and T-cells, neutrophils.
The Company believes NP-120 can reduce the infiltration of neutrophils and T-cells into the lungs where they can release glutamate and cytokines respectively. The latter can result in the highly problematic cytokine storm that contributes to the loss of lung function and ultimately death as has been reported in COVID-19 infected patients.
About Algernon Pharmaceuticals Inc.
Algernon is a drug re-purposing company that investigates safe, already approved drugs for new disease applications, moving them efficiently and safely into new human trials, developing new formulations and seeking new regulatory approvals in global markets. Algernon specifically investigates compounds that have never been approved in the U.S. or Europe to avoid off label prescription writing.
Algernon has filed new intellectual property rights globally for NP-120 (Ifenprodil) for the treatment of respiratory diseases and is working to develop a proprietary injectable and slow release formulation.
CONTACT INFORMATION
Christopher J. Moreau
CEO
Algernon Pharmaceuticals Inc.
604.398.4175 ext 701
I follow them on LinkedIn and it was posted earlier.
#Algernonnews
Algernon.Announcement at 11am central today on Biopub!!!
Algernon.Announcement at 11am central today on Biopub!!!
VERY!!!!!
I sure can’t wait until they do!!!
I’m looking forward to some positive results.
Thanks Shell3!!
I’m holding tight and I’m ready to take this ride....reminds me of the BLOZF days before it explode to the upside.
Thanks for all of the detailed DD AMG!!
I’m looking forward to this ride which I know some of us have been on for a very long time.
Good Luck everyone!
Thanks for all of the detailed DD AMG!!
I’m looking forward to this ride which I know some of us have been on for a very long time.
Good Luck everyone!
Good luck!!
I understand...I tried picking up an extra 60,000 shares of BLOZF years ago at .05 but Wells Fargo had them blocked :( that 3k could have been 100k
I don’t think they are but I do feel there’s plenty of space for competition in this industry.
There are plenty of buildings that need advanced security around the world.
Hello Smoki,
Anything specific that’s building your confidence to buying more shares.
Wish you the best!!
At this point we will be very ripe for a buyout.
2019 NASH Summit in London starts today and I noticed Owlstone will be there and didn't notice anything from Algernon. It's interesting to see the focus on Nash and Fatty Liver Disease once Yost was announced as an advisor.
Thanks for posting! Looking forward to the news :)
Great job!! All my chips were in otherwise I would have loaded up as well at $1.00.
Looks like Owlestone is interested in Liver Disease breath testing.
Hmmm...coincidence?
Me too. They're hopefully done holding it down and the 540,000 short shares are starting to cover. Once the news hits we'll be at a 52week high in a matter of days.
This is for anyone who wants to make some money.
Buy lots of shares and you’ll be rich $$$$!!!
100% agree
I agree that they’re ripe for a buy out but I hope they’re able to start generating some sales and get to $6-7 before we double from there. If you noticed the big money got in on the $70 million dollar deal took their warrant and sold most of the shares. Also if you’ve noticed with no institutional buying and on the US OTC pink sheets there’s still shorts that are holding it down are the same ones that made the money on the way up.
Great post! Now is the time to grab up some pre-revenue shares otherwise you'll wish you had and most of us on this board have been that trader before.
I remember when BLOZF went to .05 from my original investment of .20(avg.) but than I sold it at $1.61!!! Here's for $1.61 one day for BTHCF :)!!!!!
It is!!! This is the beginning with a 33B dollar world wide Tier 1 security company. We still have 500,000 Market Movers shorting this company but hopefully that was cut in half today alone. More news and revenue will eat up the rest of these shorts than we'll see it go past our all time highs.
Any price below $1.40 is a great entry point for this stock.
The great thing about this is that they uncovered it. The actual volume for that day wasn't even above average and then it rested lows prior to that media announcement anyway....so thanks again for another great entry level :)!!